PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH to Present at Morgan Stanley Global Healthcare Conference
LYON, France --(BUSINESS WIRE)--Sep. 12, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (ADR: EYRYY) (Euronext Paris - ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that
View HTML
Toggle Summary ERYTECH to Present at Morgan Stanley Global Healthcare Conference
LYON, France --(BUSINESS WIRE)--Sep. 12, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (ADR: EYRYY) (Euronext Paris - ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that
View HTML
Toggle Summary ERYTECH Reports First Half 2017 Financial Results and Provides Business Update
Conference call and webcast scheduled for Tuesday, September 12 th at 02:30 pm CEST / 08:30 am EDT Positive final results from Phase 2b study of eryaspase (GRASPA®) for the treatment of metastatic pancreatic cancer presented at the European Society for Medical Oncology (ESMO) 2017 Congress Meeting
View HTML
Toggle Summary ERYTECH Reports First Half 2017 Financial Results and Provides Business Update
Conference call and webcast scheduled for Tuesday, September 12 th at 02:30 pm CEST / 08:30 am EDT Positive final results from Phase 2b study of eryaspase (GRASPA®) for the treatment of metastatic pancreatic cancer presented at the European Society for Medical Oncology (ESMO) 2017 Congress Meeting
View HTML
Toggle Summary ERYTECH Announces Positive Full Results from Phase 2b Study of Eryaspase in Combination with Chemotherapy for Treatment of Metastatic Pancreatic Cancer in Second-Line
Full data demonstrates statistically significant improvement in both overall survival and progression-free survival for eryaspase as second-line treatment of metastatic pancreatic cancer Data to be presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid ( September
View HTML
Toggle Summary ERYTECH Announces Positive Full Results from Phase 2b Study of Eryaspase in Combination with Chemotherapy for Treatment of Metastatic Pancreatic Cancer in Second-Line
Full data demonstrates statistically significant improvement in both overall survival and progression-free survival for eryaspase as second-line treatment of metastatic pancreatic cancer Data to be presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid ( September
View HTML
Toggle Summary ERYTECH to Host Second Quarter 2017 Conference Call and Business Update
LYON, France --(BUSINESS WIRE)--Sep. 6, 2017-- Regulatory News : ERYTECH (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Second Quarter 2017
View HTML
Toggle Summary ERYTECH to Host Second Quarter 2017 Conference Call and Business Update
LYON, France --(BUSINESS WIRE)--Sep. 6, 2017-- Regulatory News : ERYTECH (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Second Quarter 2017
View HTML
Toggle Summary Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –August 31st, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Sep. 6, 2017-- Regulatory News : Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut (1) voting rights   Total of net (2) voting rights
View HTML
Toggle Summary Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –August 31st, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Sep. 6, 2017-- Regulatory News : Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut (1) voting rights   Total of net (2) voting rights
View HTML
Top